During the past decade, Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 22 clinical trials were completed, i.e. on average, 88% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 14 clinical trials were completed. i.e. 155.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" #1 sponsor was "Biogen" with 3 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Baxalta now part of Shire" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" #1 collaborator was "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Hexal AG" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" are "Alzheimer's Disease" (4 trials), "Ulcerative Colitis" (4 trials), "Atrial Fibrillation" (2 trials), "Chronic Inflammatory Demyelinating Polyradiculoneuropathy" (2 trials) and "Crohn's Disease" (2 trials). Many other conditions were trialed in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" in a lesser frequency.

Most popular intervention types in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" are "Drug" (30 trials), "Biological" (6 trials), "Other" (5 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "HYQVIA" (2 trials), "Mirikizumab" (2 trials), "0.25% albumin placebo solution with rHuPH20" (1 trials) and "ALZT-OP1a" (1 trials). Other intervention names were less common.

The vast majority of trials in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie" are 39 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 21 completed trials in Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 0 trials that are defined as “Not Applicable".

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie has several departments that took part in Clinical trials: "Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie; Klinika Neurochirurgii i Neurochirurgii Dzi" - 2 trials, "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie Oddział Gastroenterologii" - 2 trials, "Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie; Klinika Neurologii" - 2 trials